Belgium-based drug discovery and development company Apitope has regained global rights to its compound, ATX-MS-1467.

The potentially disease-modifying therapy ATX-MS-1467 is used to treat multiple sclerosis (MS) and completed a Phase II clinical trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The company said it will regain all rights and clinical data associated with the compound under the agreement with Merck.

Apitope CEO Dr Keith Martin said: “We believe ATX-MS-1467 has enormous potential for treating MS patients. We are pleased to be regaining the rights to the compound, as well as the clinical data.

"We believe ATX-MS-1467 has enormous potential for treating MS patients. We are pleased to be regaining the rights to the compound, as well as the clinical data."

“This will provide us with greater flexibility and control in the clinical development of ATX-MS-1467. We are now able to pursue new business collaborations to enable the further development of this promising treatment.

See Also:

“We appreciate the efforts made by the Merck KGaA, Darmstadt, Germany, team members in advancing this programme to date.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase I clinical trial was completed in six patients with secondary progressive MS (SPMS) and a second Phase I trial in 43 relapsing MS patients.

Following the examination of the MRI results including new gadolinium-enhancing and total gadolinium-enhancing [Gd+] lesions, a fall of 78% in the number of Gd+ brain lesions was found in patients with relapsing MS treated with intradermal injection of ATX-MS-1467.

Enrolment last year in a Phase IIa clinical trial of ATX-MS-1467 in relapsing multiple sclerosis was concluded.

The outcome of the study is expected in the fourth quarter of this year.